Cardiac Tissue-Derived Cells

• US 20110014161A1
• Filed: 07/08/2010
• Published: 01/20/2011
• Est. Priority Date: 07/09/2009
• Status: Abandoned Application

• Current Assignee: Ian R. Harris, Jeffrey S. Kennedy, Susan Munga, Xiaozhen Wang, Yang Jing
• Original Assignee: Ian R. Harris, Jeffrey S. Kennedy, Susan Munga, Xiaozhen Wang, Yang Jing
• Inventors: YANG, JING, MUNGA, SUSAN, WANG, XIAOZHEN, HARRIS, IAN R., KENNEDY, JEFFREY S.
• Application Number:
  US12/832,609
• Publication Number:
  US 20110014161A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/34 Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes vascular smooth muscle A61K35/44
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells
• CPC Class Codes: C12N 5/0662 Stem cells

Abstract

The present invention is directed to methods and compositions for repairing damaged myocardium using human cardiac tissue-derived cells. In particular, the present invention provides methods and compositions for repairing damaged myocardium using expanded human cardiac tissue-derived cells that do not express telomerase.

Claims

1. A method to produce cardiac tissue-derived cells that do not express telomerase, comprising the steps of:

a. Obtaining heart tissue,

b. Dissociating the heart tissue,

c. Digesting the heart tissue to release cells,

d. Removing cardiomyocytes from the released cells, and

e. Culturing the remaining cells.

2. The method of claim 1, wherein the heart tissue is dissociated manually.

3. The method of claim 1, wherein the heart tissue is dissociated mechanically.

4. The method of claim 1, wherein the heart tissue is digested with at least one enzyme selected from the group consisting of collagenase and dispase.

5. The method of claim 1, wherein an entire heart is used as the source for the cardiac tissue.

6. The method of claim 1, wherein the cardiac tissue-derived cells that do not express telomerase express at least one of the following markers:

CD49e, CD105, CD59, CD81, CD34, and CD117.

7. The method of claim 1, wherein the cardiac tissue-derived cells that do not express telomerase do not express at least one of the following markers:

MDR, CD19, CD16, CD46, CD106 and Isl-1.

8. A method to treat damaged myocardium in a patient comprising the steps of:

a. Obtaining a population of cardiac tissue-derived cells that do not express telomerase, and

b. Administering the population of cardiac tissue-derived cells to the patient in an amount sufficient to treat the damaged myocardium.

9. The method of claim 8, wherein the administration of the cardiac tissue-derived cells is via direct injection into the damaged myocardium.

10. The method of claim 8, wherein the administration of the cardiac tissue-derived cells is via direct injection into the area of the heart immediately surrounding the damaged myocardium.

11. A method to repair damaged myocardium in a patient comprising the steps of:

a. Obtaining a population of cardiac tissue-derived cells that do not express telomerase, and

b. Administering the population of cardiac tissue-derived cells to the patient in an amount sufficient to repair the damaged myocardium.

12. The method of claim 11, wherein the administration of the cardiac tissue-derived cells is via direct injection into the damaged myocardium.

13. The method of claim 11, wherein the administration of the cardiac tissue-derived cells is via direct injection into the area of the heart immediately surrounding the damaged myocardium.

14. A purified population of human cardiac tissue-derived cells that do not express telomerase express, that express at least one of the following markers:

CD49e, CD105, CD59, CD81, CD34, and CD117.

15. A purified population of human cardiac tissue-derived cells that do not express telomerase express, that do not express at least one of the following markers:

MDR, CD19, CD16, CD46, CD106 and Isl-1.